November 19, 2017 10:57 PM Eastern Daylight Time

BUSINESS WIRE

Riassunto: Samsung Bioepis ottiene l'autorizzazione alla commercializzazione di ONTRUZANT®, il primo biosimilare di trastuzumab in Europa

Samsung Bioepis R&D Center. (Photo: Business Wire)

Samsung Bioepis R&D Center. (Photo: Business Wire)

Opens in new window

Download

Full Size JPEG, 5616x3744, 3.5 MB
Small JPEG, 480x320, 79.3 KB
Preview JPEG, 144x96, 17.5 KB
Thumbnail JPEG, 72x48, 9.8 KB

Smart Multimedia Gallery

Christopher Hansung Ko, President & CEO of Samsung Bioepis. (Photo: Business Wire)

Christopher Hansung Ko, President & CEO of Samsung Bioepis. (Photo: Business Wire)

View and Share Photo

Samsung Bioepis R&D Center. (Photo: Business Wire)

Samsung Bioepis R&D Center. (Photo: Business Wire)

Samsung Bioepis R&D Center. (Photo: Business Wire)

Samsung Bioepis R&D Center. (Photo: Business Wire)

View and Share Photo

http://www.businesswire.it/multimedia/it/20171119005085/it/4230127/

View and Share Logo

Share

Email

All News | News with Multimedia > Press Release: Riassunto: Samsung Bioepis ottiene l'autorizzaz...